Treatment of ovarian cancer with intraperitoneal chemotherapy.
In early 2006, the National Cancer Institute (NCI) issued a Clinical Announcement suggesting that intraperitoneal (IP) chemotherapy should become the standard of care for patients with newly diagnosed stage III optimally debulked epithelial ovarian cancer. IP chemotherapy, the administration of chemotherapy or biologic therapy via catheter into the peritoneal space, is new to many healthcare providers (physicians, nurses, and pharmacists). The goals of this article are to address the rationale for IP chemotherapy, present the data supporting its use, and describe the nursing management of patients undergoing this treatment. Education of patients and staff regarding IP therapy is essential for successful patient outcomes.
Department of Nursing, Memorial Sloan-Kettering Cancer Center at Sleepy Hollow, Sleepy Hollow, New York, USA.
Catherine
C
Hydzik
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D015994:Incidence; D007263:Infusions, Parenteral / Q000379:methods* / Q000592:standards; D054547:National Cancer Institute (U.S.); D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality; D012449:Safety; D017741:Survivors; D014481:United States / Q000453:epidemiology
D000970:Antineoplastic Agents